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DCM-Causing Mutation E361G in Actin Slows Myofibril Relaxation
Kinetics and Uncouples Myofibril Ca2D Sensitivity from Protein
Phosphorylation
Petr G. Vikhorev, Ross Wilkinson, Weihua Song, O’ Neal Copeland,
Steven B. Marston, Michael A. Ferenczi.
Imperial College, London, United Kingdom.
Previous experiments using the unloaded in vitro motility assay have shown
that the myofilament Ca2þ-sensitivity is modulated by phosphorylation by
PKA of troponin I (Ser 22 and 23) and that the DCM-causing mutation
ACTC E361G uncouples this relationship. Here, we determine whether this
also happens in heart muscle myofibrils producing isometric force. Myofibrils
were isolated from wild-type and ACTC E361G mouse hearts. We know that
TnI and MyBP-C phosphorylation levels are high in normal mouse heart (1.4
molPi/mol TnI). To reduce the phosphorylation level of TnI and MyBP-C,
mice were injected with a high dose of beta-adrenoceptor agonist propranolol
which reduced phosphorylation of both TnI and MyBP-C by 70-80-%. Myofi-
brils were isolated from propranolol-treated and untreated mouse hearts. Then
we measured contraction in single myofibrils with a Ca2þ-jump protocol using
a range of Ca2þconcentrations. The maximum isometric force was the same for
phosphorylated and dephosphorylated WT and ACTC E361G mouse myofi-
brils. The duration of the linear slow phase of relaxation was longer (1.4-1.8
fold) and the rate of the fast phase was reduced (1.1-1.4 fold) for the ACTC
E361G TG compared to WT. The Ca2þ-sensitivity of isometric force was
increased 1.4-fold (p=0.021) when WT myofibrils were dephosphorylated. In
contrast the ACTC E361G Ca2þ-sensitivity was not altered by dephosphoryla-
tion. This pattern was also apparent in the rates of relaxation. Comparing de-
phosphorylated WT vs WT, the duration of the linear slow phase was longer
and the rate of the fast phase was reduced but dephosphorylation did not change
the kinetics of E361G myofibril. Thus the ACTC E361G mutation fully un-
coupled Ca2þ sensitivity from the level of TnI and MyBP-C phosphorylation
in intact myofibrils as we have seen with IVMA.
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There is a Limit to the Changes in Myofilament Ca2D-Sensitivity due to
Myopathies
Andrew E. Messer, Steven B. Marston, Christopher R. Bayliss,
Massimiliano Memo.
Imperial College - NHLI, London, United Kingdom.
We have investigated Ca2þ-sensitivity changes in cardiac and skeletal muscle
due to mutations or phosphorylation of troponin I (TnI) using the in vitro mo-
tility assay.
In normal heart, TnI phosphorylation alters myofibrillar Ca2þ-sensitivity and
increases the speed of Ca2þ-dissociation (lusitropic effect). When end-stage
heart failure samples with a reduced level of phosphorylation were looked at,
the average Ca2þ-sensitivity change was x2.650.24.
Eight dilated cardiomyopathy (DCM) mutations have been looked at in all
components of the thin filament (Actin E361G, TnT R141W and DK210,
TnI K36Q, TnC G159D and Tm E40K, E54K and D230N). Although they
all have differing effects on Ca2þ-sensitivity (some increased it and some de-
creased it) the average Ca2þ-sensitivity change was x2.050.16.
The actin E99K hypertrophic cardiomyopathy (HCM) mutation causes an in-
crease in Ca2þ-sensitivity of x2.5 but a literature search looking at 21 other
HCM mutations in every sarcomeric protein has found an average Ca2þ-sensi-
tivity change of x1.850.13.
Awide range of skeletalmyopathieswere looked atwhich either caused a gain of
function (TPM2DK49,DE139,ACTA1K326N and TPM3DK7) or loss of func-
tion (TPM2 E117K, R91P and TPM3 A4V, L100M and R167C). The mean
changes of Ca2þ-sensitivity were x1.850.3 and x2.750.4 respectively.
It is remarkable that mutations causing a range of different striated muscle my-
opathies have such a similar and limited effect on myofilament Ca2þ-sensitivity
and that phosphorylation of troponin I regulates Ca2þ-sensitivity over the same
range. We have found in DCM and HCM that Ca2þ-sensitivity is uncoupled
from the level of TnI phosphorylation and tends to the Ca2þ-sensitivity charac-
teristic of phosphorylated wild-type muscle at all phosphorylation levels. It is
tempting to speculate that the 2-fold change represents a transition between
two activation states of the thin filament.
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Effect of the Troponin I Restrictive Cardiomyopathy Mutation R145W on
Protein Expression in Murine Murine Hearts
Ziyou Cui, Gayathri Venkatraman, Soyun M. Hwang, Aldrin V. Gomes.
University of California, Davis, Davis, CA, USA.
Restrictive cardiomyopathy (RCM) is a relatively rare type of cardiomyopathy
but is assocated with a high incidence of sudden cardiac death (SCD). TheR145W mutation in troponin I have been shown to be associated with RCM
and in patients with this mutation SCD has been found to occur. A transgenic
mouse model of RCM expressing troponin I R145W showed increased calcium
sensitivity of force development and impaired muscle relaxation. Isobaric tags
for relative and absolute quantitation (iTRAQ), a non-gel-based technique used
to quantify proteins from different sources in a single experiment, was used to
determine the differences between hearts from 3 month old transgenic control
mice (mice expressing human cardiac troponin I) and R145W mice (mice ex-
pressing human troponin I with the R145W mutation). Four hearts each from
R145W and wild-type transgenic mice were proteomically investigated and
several signaling pathways were found to be affected by the R145W mutation.
Increases in enzymes involved in ATP production (such as NAD(P) transhydro-
genase), kinases (calmodulin dependent protein kinase II beta), intermediate
filament proteins (desmin), de-ribosylating enzyme (ADP-ribosylarginine
hydrolase), proteolytic enzymes (tripeptidy peptides II), glycolytic enzymes
(glyceraldehyde-3-phosphate dehydrogenase), and stress related proteins
(inducible heat shock protein 90aa). At the proteolytic level the activity of
the proteasome was decreased in hearts from R145W transgenic mice. No
change in the protein expression levels of the 20S protein PSMA6 or the 19S
protein Rpt1 was observed in these hearts. These results suggest that the
RCM mutation R145W is associated with significant and complex changes in
cardiac protein expression.
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Mutations in Cardiac Myosin Binding Protein - C Associated with
Hypertrophic Cardiomyopathy Alter Structure, F-Actin Binding and
Phosphorylation
Cecily E. Oakley1, Alistair V. Edwards1, Joo-Mee Hwang1,
Stuart J. Cordwell1, Piotr G. Fajer2, Louise J. Brown3, Murat Kekic1,
Brett D. Hambly1.
1University of Sydney, Sydney, Australia, 2Florida State University,
Tallahassee, FL, USA, 3Macquarie University, Sydney, Australia.
A common cause of hypertrophic cardiomyopathy (HCM) is mutations and
modifications of the sarcomeric protein cardiac myosin binding protein C
(MyBPC). MyBPC binds to the F-actin thin filament via its N-terminus, the
myosin thick filament backbone via its C-terminus, and reversibly binds to
the myosin-S2 neck region (when de-phosphorylated). The functional conse-
quences of nine hypertrophic cardiomyopathy mutations within the N-terminal
phosphorylation region, domains C1C2 were determined. Of the nine HCM
mutations investigated, only two (Tyr237Ser and His257Pro) showed de-
creased solubility and altered folding, compared to the wild-type C1C2, as
measured by circular dichroic spectroscopy. Phosphorylation did not alter
the secondary structure content of C1C2. Wild-type C1C2 binds F-actin with
1:1 stoichiometry and micromolar affinity (Kd ~ 7 mM), using a co-
sedimentation assay. All mutants exhibited weaker binding to actin, except
for Asp228Asn and Arg326Gln, which bound similarly to WT. Protein kinase
A phosphorylation activity was assessed in four HCMmutants, located in close
proximity to the phosphorylation sites. The Gly278Glu mutation inhibited
phosphorylation, Arg326Gln and Leu352Pro increased the rate, while no
difference was observed for the Gly279Ala mutation. The order of protein
kinase A phosphorylation of C1C2 was determined to be: phosphorylation of
Ser284 (Site B), followed by Ser275 (Site A). The third and final phosphate
was added at Ser304 (Site C), at a much slower rate (0.015 min 1). The effects
of hypertrophic cardiomyopathy mutations on C1C2 structure and function
were consistent with the mild phenotype associated with these mutations.
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Electron Microscopy and 3D Reconstruction of Regulated Thin Filaments
Decorated with Cardiac Myosin Binding Protein C
Ji Young Mun1, James Gulick2, Jeffrey Robbins2, Roger Craig1.
1UMass Medical School, Worcester, MA, USA, 2Cincinnati Children’s
Hospital, Cincinnati, OH, USA.
Myosin binding protein C (MyBP-C) is an accessory protein of striated muscle
thick filaments and a modulator of cardiac muscle contraction. Defects in the
cardiac isoform, cMyBP-C, cause heart disease. cMyBP-C comprises eleven
10 kDa immunoglobulin- and fibronectin-like domains, numbered C0-C10
from the N-terminus, and a MyBP-C-specific motif between C1 and C2.
In vitro studies show that, in addition to binding to the thick filament via its
C-terminal region, cMyBP-C can also interact with actin via its N-terminal do-
mains, modulating actin motility. Neutron scattering and 3D EM reconstruc-
tions of F-actin decorated with N-terminal fragments of cMyBP-C suggest
that cMyBP-C binds to subdomain 1 of actin close to the low Ca2þ binding
site of tropomyosin. This suggests that cMyBP-C might modulate thin filament
activity by physically interfering with tropomyosin regulatory movements on
actin, a possibility strengthened by solution kinetics observations (White and
